Elevance Health Shares Plunge After Legal Setback, $500M Volume Ranks 171st

Elevance Health (ELV) traded with a 0.13% decline on August 21, 2025, with a trading volume of $500 million, a 25.72% drop from the previous day, ranking 171st in market activity. The stock’s underperformance was driven by a legal setback that threatens to cost the insurer $375 million in 2025 Medicare Advantage bonus payments. A federal judge dismissed Elevance’s challenge to the Centers for Medicare & Medicaid Services (CMS) rating methodology, upholding the agency’s authority to set standards. The ruling means one of Elevance’s contracts, calculated at 3.749565 stars, was rounded down to 3.5, falling short of the four-star threshold required for bonus eligibility. The case, which Elevance argued was “arbitrary and capricious,” highlights regulatory risks in the Medicare Advantage sector, where CMS star ratings directly impact both federal incentives and consumer enrollment decisions.

The decision sets a precedent that could deter insurers from contesting CMS methodologies in court, shifting focus toward operational improvements and member satisfaction. Elevance’s valuation reflects these pressures, trading at a forward P/E ratio of 9.72, well below the industry average of 15.25. Analysts’ consensus estimate for 2025 earnings stands at $30.15 per share, signaling an 8.8% decline year-over-year. Despite its low valuation, Elevance carries a Zacks Rank #5 (Strong Sell), underscoring challenges in navigating rising medical costs and regulatory scrutiny. The stock’s year-to-date loss of 16.1% contrasts with the industry’s modest 0.2% growth, reflecting broader sector struggles.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to present delivered a 1-day return of 1.98% and a total return of 7.61% over 365 days. The approach had a Sharpe ratio of 0.94, indicating favorable risk-adjusted returns, though it faced a maximum drawdown of -29.16% during market downturns.